JonesTrading analyst Soumit Roy has maintained their bullish stance on AVBP stock, giving a Buy rating on August 12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors that highlight ArriVent BioPharma, Inc.’s promising future prospects. The company is expected to release pivotal topline Phase 3 data for firmonertinib in the treatment of 1L EGFR ex20ins mutated NSCLC in early 2026, which is a significant milestone that could enhance its market position. Additionally, ArriVent plans to present final data from the EGFR PACC Phase 1b trial at the WCLC 2025, further solidifying its research advancements.
Another reason for the Buy rating is the company’s strong financial position, with approximately $335.6 million in cash and marketable securities, ensuring a solid cash runway. The valuation analysis, which includes DCF, NPV, and PE-based valuations, suggests a price target of $45, driven by potential peak sales and contributions from firmonertinib in different NSCLC mutations. These factors collectively indicate a positive outlook for ArriVent BioPharma, Inc., justifying the Buy recommendation.
In another report released on August 12, Citi also maintained a Buy rating on the stock with a $33.00 price target.